| 000 | 01848cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030406.0 | ||
| 008 | 110502s2009 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.19.03.Ph.D.2009.Ra.R | ||
| 100 | 0 | _aRania Salah Abdelaziz | |
| 245 | 1 | 4 |
_aThe role of CD86 and vascular endothelial growth factor in acute myeloid leukemia / _cRania Salah Abdelaziz ; Supervised Magda M. A. Assem , Basma M. Elgamal , Sherine I. Salem |
| 246 | 1 | 5 | _aدور سى دى 86 وعامل النشوء الوعائى الدموى فى سرطان الدم الميلودى الحاد |
| 260 |
_aCairo : _bRania Salah Abdelaziz , _c2009 |
||
| 300 |
_a212P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Clinical Pathology | ||
| 520 | _aAML is the most frequent type of leukemia in adult . Recognition and destruction of leukemic blasts by the immune system is of great interest for the development of immuntherapeutic strategies in AML . T- cell activation requires T-cell receptor recognition and binding to major histocompatability complex (MHC) complex/angtigen presented by an antigen-presenting cell (APC) and the binding of ligands for the T - cell costimulatory receptors CD28 and CTLA - 4, ie, CD80/B7 - 1 and CD86/B7 - 2, respectively | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aCD80 | |
| 653 | 4 | _aCD86 | |
| 653 | 4 | _aVasclar Endothelial Growth Factor | |
| 700 | 0 |
_aBasma Mostafa Elgamal , _eSupervisor |
|
| 700 | 0 |
_aMagda Mahmoud A. Assem , _eSupervisor |
|
| 700 | 0 |
_aSherine Ibrahim Salem , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aFatma _eCataloger |
||
| 905 |
_aNazla _eRevisor |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c33728 _d33728 |
||